Stem Cell ‘Living Bandage’ for Knee Injuries Trialled in Humans

Newswise — A ‘living bandage’ made from stem cells, which could revolutionise the treatment and prognosis of a common sporting knee injury, has been trialled in humans for the first time by scientists at the Universities of Liverpool and Bristol.

Meniscal tears are suffered by over one million people a year in the US and Europe alone and are particularly common in contact sports like football and rugby. 90 per cent or more of tears occur in the white zone of meniscus which lacks a blood supply, making them difficult to repair. Many professional sports players opt to have the torn tissue removed altogether, risking osteoarthritis in later life.

The cell bandage has been developed by Bristol University spin-out company Azellon, and is designed to enable the meniscal tear to repair itself by encouraging cell growth in the affected tissue.

A prototype version of the cell bandage was trialled in five patients, aged between 18 and 45, with white-zone meniscal tears. The trial received funding support from Innovate UK and the promising results have been published today in the journal Stem Cells Translational Medicine.

The procedure involved taking stem cells, harvested from the patient’s own bone marrow, which were then grown for two weeks before being seeded onto a membrane scaffold that helps to deliver the cells into the injured site. The manufactured cell bandage was then surgically implanted into the middle of the tear and the cartilage was sewn up around the bandage to keep it in place.

All five patients had an intact meniscus 12 months post implantation. By 24 months, three of the five patients retained an intact meniscus and had returned to normal knee functionality whilst the other two patients required surgical removal of the damaged meniscus due to a new tear or return of symptoms.

Professor Anthony Hollander, formerly of Bristol and now Chair of Stem Cell Biology at the University of Liverpool and Founder and Chief Scientific Officer of Azellon, said: “The cell bandage trial results are very encouraging and offer a potential alternative to surgical removal that will repair the damaged tissue and restore full knee function.

“We are currently developing an enhanced version of the cell bandage using donor stem cells, which will reduce the cost of the procedure and remove the need for two operations.”

The cell bandage was produced by the Advanced Therapies Unit at the NHS Blood & Transplant facility in Speke, Liverpool and implanted into patients at Southmead Hospital in Bristol, under the supervision of Professor Ashley Blom, Head of Orthopaedic Surgery at the University of Bristol.

Professor Blom, from Bristol’s School of Clinical Sciences, commented: “The cell bandage offers an exciting potential new treatment option for surgeons that could particularly benefit younger patients and athletes by reducing the likelihood of early onset osteoarthritis after meniscectomy.”

A spokesperson for Innovate UK said: “Turning stem cell research into clinical and commercial reality requires close collaboration between businesses, universities, and Hospitals. It’s great to see this inter-disciplinary approach has led to such an exciting outcome from this first-in-human trial.”

ENDS

The paper ‘Repair of torn avascular meniscal cartilage using undifferentiated autologous mesenchymal stem cells: from in vitro optimisation to a first-in-human study is published in Stem Cells Translational Medicine. It will be available online once the embargo has lifted at http://onlinelibrary.wiley.com/doi/10.1002/sctm.16-0199/abstract

Azellon is a spin-out company from the University of Bristol that was co-founded by Professor Anthony Hollander and is backed by a syndicate of investors including IP Group plc, Oxford Technology Management, Wyvern Seed Fund and Hugh Osmond. Professor Hollander came to national prominence as part of the academic team that saved the life of Claudia Castillo, after developing the first tissue-engineered trachea (windpipe) using the patient’s own stem cells. Azellon’s focus is on developing stem cell therapy for the repair of avascular meniscal tears. Azellon has received grant support from the Wellcome Trust and Innovate UK. For more information, please visit www.azellonctx.com

Innovate UK is the UK’s innovation agency. We are business focused and drive disruptive innovation. We fund and connect pioneering businesses so they can create the products, processes and industries of the future. We boost productivity, increase exports and help the UK economy grow. For further information and to stay updated on our latest news visit www.gov.uk/innovateuk, follow us on Twitter at @innovateuk or subscribe to our YouTube channel at www.youtube.com/InnovateUK.

NHS Blood and Transplant (NHSBT) is a joint England and Wales Special Health Authority. We are responsible for ensuring a safe and efficient supply of blood and associated services to the NHS in England. We are also the organ donation organisation for the UK and are responsible for matching and allocating donated organs. NHSBT is, regulated by the Human Tissue Authority and MHRA. In addition to expertise in our production facilities in Liverpool and Filton, Bristol, our logistical skills and infrastructure enable delivery of both viable cells for processing, and effective therapies to patients through validated cold supply chains.

SEE ORIGINAL STUDY